Coronary Artery Bypass Graft News and Research RSS Feed - Coronary Artery Bypass Graft News and Research

Cumberland launches new Vaprisol product

Cumberland launches new Vaprisol product

Cumberland Pharmaceuticals Inc. today announced the launch of its active promotional campaign to support its new Vaprisol® product. [More]
Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Study: Repeat sternotomy for surgical aortic valve replacement safe for octogenarian patients

Surgical aortic valve replacement generally improves patients' symptoms and prolongs survival. However, the perceived risk of surgical aortic valve replacement in patients over 80 may result in surgery being denied or a recommendation for alternative therapy. Investigators at the Mayo Clinic challenge the way these patients have been managed. [More]
FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

FDA approves Iroko Pharmaceuticals’ TIVORBEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved TIVORBEX™ (indomethacin) capsules, a nonsteroidal anti-inflammatory drug (NSAID), at 20 mg and 40 mg doses for the treatment of mild to moderate acute pain in adults. [More]
Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt announces commercial launch of PENNSAID

Mallinckrodt today announced the commercial launch of PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%). PENNSAID 2% is a topical non-steroidal anti-inflammatory drug (NSAID) approved for use in the treatment of the pain of osteoarthritis of the knees. [More]
FDA approves New Drug Application for PENNSA 2%

FDA approves New Drug Application for PENNSA 2%

Mallinckrodt today announced that the U.S. Food and Drug Administration has approved the New Drug Application for PENNSAID (diclofenac sodium topical solution) 2% w/w. PENNSAID 2% is a topical non-steroidal anti-inflammatory drug approved for use in the treatment of the pain of osteoarthritis of the knee(s). [More]
FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

FDA accepts Iroko Pharmaceuticals' ZORVOLEX sNDA for review

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, announced that the U.S. Food and Drug Administration has accepted for review the Supplemental New Drug Application for ZORVOLEX (diclofenac), a lower dose nonsteroidal anti-inflammatory drug, for the proposed indication of treatment of osteoarthritis pain in adults. ZORVOLEX was approved by FDA in October 2013 for the treatment of mild to moderate acute pain in adults. [More]
Aortic valve replacement improves survival and outcomes in elderly patients

Aortic valve replacement improves survival and outcomes in elderly patients

Jose Augusto Barreto-Filho, M.D., Ph.D., of the Federal University of Sergipe and the Clinica e Hospital Sao Lucas, Sergipe, Brazil, and colleagues assessed procedure rates and outcomes of surgical aortic valve replacement (AVR) among 82,755,924 Medicare fee-for-service beneficiaries between 1999 and 2011. [More]
Study reveals substantial economic impact of HAIs following cardiac surgery

Study reveals substantial economic impact of HAIs following cardiac surgery

After cardiac surgery, healthcare-associated infections (HAIs) are common complications associated with increased morbidity, mortality, and use of resources. [More]
Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals net revenue decreases from $12.5 to $6.5 million

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced third quarter 2013 financial results. [More]
FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

FDA approves Iroko Pharmaceuticals’ ZORVOLEX capsules

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products. [More]
Coronary artery bypass graft surgery provides better health status, quality of life in diabetic patients

Coronary artery bypass graft surgery provides better health status, quality of life in diabetic patients

For patients with diabetes and coronary artery disease in more than one artery, treatment with coronary artery bypass graft surgery provided slightly better health status and quality of life between 6 months and 2 years than procedures using drug-eluting stents, although beyond 2 years the difference disappeared, according to a study in the October 16 issue of JAMA. [More]
Inflating blood pressure cuff ahead of heart bypass surgery reduces heart injury

Inflating blood pressure cuff ahead of heart bypass surgery reduces heart injury

Inflating a blood pressure cuff on the upper arm just ahead of heart bypass surgery reduces heart injury and might even improve bypass patients’ long-term survival, according to an Article published in The Lancet. [More]

Report reveals off-pump CABG surgery failed to show any improvement in short-term mortality

In a Special Report in the current issue of Circulation, Boston Medical Center cardiothoracic surgeon Harold Lazar, MD, has found that off-pump coronary artery bypass graft (OPCAB) surgery has failed to show any significant improvement in short-term morbidity or mortality as compared to the traditional on-pump coronary artery bypass graft (CABG) surgery. [More]
Different financial incentives between Medicare Advantage and FFS influence use of CV procedures

Different financial incentives between Medicare Advantage and FFS influence use of CV procedures

In a study that included nearly 6 million Medicare Advantage and Medicare fee-for-service beneficiaries from 12 states, rates of angiography and percutaneous coronary interventions were significantly lower among Medicare Advantage beneficiaries and geographic variation in procedure rates was substantial for both payment types, according to a study in the July 10 issue of JAMA. [More]
STREAM trial: Treatment with tenecteplase before hospital transfer benefits some

STREAM trial: Treatment with tenecteplase before hospital transfer benefits some

A clot-busting therapy may benefit some heart attack patients who cannot have immediate angioplasty, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. [More]
On and off-pump coronary artery bypass surgery equally safe, effective for older patients

On and off-pump coronary artery bypass surgery equally safe, effective for older patients

Older patients did as well after undergoing coronary bypass surgery off-pump as they did with the more costly "on-pump" procedure using a heart-lung machine to circulate blood and oxygen through the body during surgery, according to research presented today at the American College of Cardiology's 62nd Annual Scientific Session. [More]
Tranexamic acid role in coronary bypass surgery

Tranexamic acid role in coronary bypass surgery

Tranexamic acid balances the increased bleeding risk associated with recent clopidogrel use in patients undergoing on-pump coronary artery bypass grafting, shows a randomized trial. [More]

STD Med, Pavilion announce joint investment to launch Saphena Medical

Pavilion Medical Innovations L.L.C. of Norwell, MA and STD Med, Inc. of Stoughton, MA are pleased to announce a joint investment to launch Saphena Medical, Inc., a new cutting edge medical device company focused on Endoscopic Vein Harvesting technologies. [More]

Kips Bay Medical initiates eMESH I clinical feasibility trial in atherosclerotic disease

Manny Villafaña, Chairman and CEO of Kips Bay Medical Inc. announced that on February 5, 2013, the first U.S. patient was implanted with the eSVS Mesh at the Northeast Georgia Heart Center in Gainesville, Georgia. [More]
Sanofi introduces LeGoo gel to temporarily stop blood flow during cardiovascular surgery

Sanofi introduces LeGoo gel to temporarily stop blood flow during cardiovascular surgery

Sanofi US announced the commercial launch of LeGoo, a biopolymer gel that allows surgeons to temporarily stop blood flow during surgery without the use of clamps, elastic loops or other conventional occlusion devices, which may increase risk of trauma to blood vessels. [More]